Artiva Biotherapeutics (ARTV) Liabilities and Shareholders Equity (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $106.0 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 44.6% year-over-year to $106.0 million in Q1 2026; TTM through Mar 2026 was $555.1 million, a 20.96% decrease from a year earlier, with the FY2025 full-year figure at $130.9 million, down 37.52% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $106.0 million, down from $130.9 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for ARTV reached as high as $225.6 million in Q3 2024 and fell as low as $75.9 million in Q2 2024.
• Historically, Liabilities and Shareholders Equity has averaged $151.4 million across 4 years, with a median of $148.9 million in 2025.
• Across the five-year window, Liabilities and Shareholders Equity surged 123.14% in 2025 and plunged 44.6% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $105.1 million in 2023, then soared by 99.38% to $209.6 million in 2024, then sank by 37.52% to $130.9 million in 2025, then dropped by 19.08% to $106.0 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $106.0 million in Q1 2026, $130.9 million in Q4 2025, and $148.9 million in Q3 2025.